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274 Do poor adherers enter behaviour change interventions of
inhaled therapy? Exploration of the “healthy complier” effect
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Shefﬁeld, United Kingdom; 2University of Shefﬁeld, School of Health and Related
Research (ScHARR), Shefﬁeld, United Kingdom
Background: Understanding how to support adherence is important in CF. Sys-
tematic reviews in other chronic diseases have shown associations between good
adherence and positive outcomes even when placebo is used. Such “healthy
compliers” may be more likely to enter trials and since their baseline adherence is
higher than the population as a whole the sample size of adherence intervention
studies may need adjustment and the population of interest might not be recruited.
We report baseline adherence data for people with CF (PWCF) invited to take part
in a behaviour change intervention (BCI).
Objective: Data analysis of larger study to explore the feasibility of recruiting
poorly adherent PWCF to BCI of inhaled therapy.
Methods: During a feasibility study PWCF were invited to enter an observational
cohort collecting inhaled adherence data and demographics. They were also invited
to take part in a 3 month BCI involving adherence feedback.
Results: 34 PWCF were recruited to the observational cohort, 22 of whom agreed
to receive the BCI. Overall median adherence 3 months prior to the study was 54%
(Interquartile range 17−65). Almost a half of PWCF had adherence <50%.
Characteristic Observational (n = 12) BCI (n = 22)
Male gender 6 (50) 13 (59)
Age, y 27 (24−34) 27 (23−31)
FEV1, % predicted 65 (56−76) 66 (44−79)
BMI, kg/m2 21 (19−24) 22 (19−24)
Adherence 52 (28−82) 54 (17−65)
Data are n (%) or median (interquartile range).
Conclusion: Poor adherers can be recruited to BCI studies. Though median adher-
ence was higher than in the 64 adults in Daniels’ (Chest 2011) I-Neb study (median
adherence 36%), 25% of PWCF agreeing to BCI had adherence less than 17%.
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Background: Adherence to maintenance treatments is generally poor among people
with CF (PWCF). Understanding the barriers involved is an important step to
address the adherence problem.
Objectives: To explore healthcare professionals’ and patients’ perception of the
barriers and potential solutions for those barriers to adherence with nutritional
management, inhaled therapy and exercise in CF.
Methods:
1. Delphi survey by email among CF physiotherapists and dietitians in the UK
to identify barriers and potential solutions for those barriers they have used to
support PWCF.
2. Postal open-ended questionnaire to PWCF at the Shefﬁeld Adult CF Centre to
identify barriers from their point of view and solutions they found useful.
Results: 10 replies from dietitians and 14 replies from physiotherapists were
received. Treatment burden and complexity were identiﬁed as the most important
barrier for nutritional management, inhaled therapy and exercise.
The suggested solutions for that barrier were
• better planning and organisation for nutritional management
• individualising treatment plans for inhaled therapy and exercise
Sixteen replies from PWCF were received. This identiﬁed additional barriers not
elicited from healthcare professionals, e.g. transient change in routine which may
disrupt exercise and use of inhaled therapy.
PWCF also have different focus on preferred solutions e.g. different choices of
nutritional supplements and discrete medication pots to use Creon.
Conclusion: Important barriers and potential solutions were identiﬁed. There may
be a mismatch of barrier perception between healthcare professionals and PWCF.
It is important to consider PWCF’s view in any adherence support intervention.
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Objectives: The aim of this study was to asses the adherence to the therapeutic in
adult cystic ﬁbrosis patients using a simply and validate questionnaire for chronic
diseases. Previous reports has concentrated on rates of adherence in children and
adults using self-report questionnaires, but we need to move forward to understand
how to help patients to improve their adherence.
Methods: An observational cross-sectional study was conducted in the our Adult
Cystic Fibrosis Center. An anonymous, self-report 8-item Morisky Medication
Adherence Scale (MMAS-8) was done. Three levels of adherence were considered
(low: scores >2; medium: 1 to 2; high: 0).
Results: Forty adults cystic ﬁbrosis patient completed the questionnaire (age mean
29±9 years, VEF1% mean 52±26%, male 25 (62.5%). According to the MMAS-8
test, 62.5% of the patients had low adherence, 37.5% medium and none high. Forty
percent of patients said that they have forgotten to do their treatment and more than
a half of patients said that they ever feel hassled about sticking to their treatment
plan.
Conclusion: Using a questionnaire commonly used for chronic illness, low ad-
herence was identiﬁed in our center similar to previous reports in cystic ﬁbrosis
patients. Treatment non-adherence is a common problem, although it is important
for the successful management of cystic ﬁbrosis.
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Objectives: Imprisonment can not only have profound psychological effects but
also predict poorer health for inmates during and after the period of incarceration.
This is even more important in CF, where individuals already have existing health
problems. We have worked with prison authorities to continue CF care in our few
adult CF patients serving custodial sentences and we looked at its impact on their
health.
Methods: We ensured that prison authorities enacted treatment regimes, including
physiotherapy and outpatient appointments, and measured trends in spirometry,
weight and IV days in the periods before, during and after incarceration.
Results: During the last 5 years, 5 patients attending our adult centre (1.7%) have
spent time in prison [mean detention length 7 months (range 1−13)]. For 1 patient
post-release data was incomplete. Lung function improved during incarceration
(mean %predicted FEV1: pre 55.8% versus 65.1% at release) as did weight (69.4 kg
vs 74.5 kg) and these were partially maintained afterwards (means 60.9% and
70.5 kg). IV antibiotic use also fell (47.3 mean days per year to 19.3).
Conclusion: Our data suggests that the small cohort of patients who have served
a custodial sentence suffered no deterioration in CF-speciﬁc markers of health,
in fact there was improvement which appeared to be sustained after release from
prison. Concordance with treatment and regular attendance for medical review are
particularly important elements for maintaining health in CF adults, and for those
with chaotic lifestyles these may actually improve during periods of imprisonment
as may caloriﬁc intake and physical activity.
